Highlights • Switched memory B-cells guide rituximab retreatment intervals in NMOSD • Individualised rituximab dosing maintains efficacy with less drug exposure in NMOSD • Individualised rituximab dosing is cost-effective in NMOSD • Rituximab is likely to remain a mainstay of treatment for NMOSD Abstract Background B-cell depleting treatments are widely used to modify the course of neuromyelitis optica spectrum disorder (NMOSD).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Judith M.
Contact Judith M., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack